BC Week In Review | Aug 22, 2016
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland   Business: Diagnostic   Date completed: 2016-08-16   Type: Venture financing   Raised: CHF5 million ($5.1 million)   Investors: Altos Venture; Zuercher Kantonalbank; existing investors; private investors  ...
BC Week In Review | Feb 2, 2015
Financial News

ProteoMediX financial update

ProteoMediX AG , Zurich, Switzerland   Business: Diagnostic   Date announced: 2015-01-27   Note: ProteoMediX raised CHF1 million ($1.1 million) in a second close of its series B round, bringing the total raised in the round...
BC Week In Review | Apr 14, 2014
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland   Business: Cancer, Diagnostic   Date completed: 4/9/14   Type: Venture financing   Raised: CHF3.2 million ($3.6 million)   Investors: Altos Venture; Zuercher Kantonalbank; existing investors  ...
BioCentury | Jun 4, 2012
Emerging Company Profile

ProteoMediX: Prostate's PI3K biomarkers

ProteoMedix AG is developing a multiplexed ELISA-based blood test that aims to confirm an initial PSA positive result and reduce unneeded biopsies by monitoring a quartet of biomarkers associated with alterations in PI3K signaling, a...
BC Week In Review | Jan 23, 2012
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland   Business: Cancer, Diagnostic   Date completed: 1/19/12   Type: Venture financing   Raised: CHF2.6 million ($2.7 million)   Investors: Altos Venture; private investors  ...
BC Extra | Jan 20, 2012
Financial News

ProteoMedix raises $2.7M in series A

Cancer diagnostic company ProteoMedix AG (Zurich, Switzerland) raised CHF2.6 million ($2.7 million) in a series A round led by Altos Venture with participation from private investors. ProteoMedix is developing a blood-based prostate cancer test that...
BioCentury | Oct 31, 2011
Regulation

Lessons from PSA debate

While the medical community debates a U.S. task force's recommendation against PSA screening for prostate cancer, the implications are far broader: The task force's methodology for subjectively balancing benefit and harm is being applied to...
BC Innovations | Mar 3, 2011
Cover Story

Prostate's PTEN prognosis

U.S. and European academics have separately identified new biochemical signatures that could improve prostate cancer diagnosis and monitoring. 1,2 ProteoMediX AG holds rights to the European data and plans to develop a blood-based test that...
BC Innovations | Mar 3, 2011
Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers Serum biomarkers for prostate cancer Studies in mice and in patient samples identified serum glycoproteins that could be used for prostate cancer...
Items per page:
1 - 9 of 9
BC Week In Review | Aug 22, 2016
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland   Business: Diagnostic   Date completed: 2016-08-16   Type: Venture financing   Raised: CHF5 million ($5.1 million)   Investors: Altos Venture; Zuercher Kantonalbank; existing investors; private investors  ...
BC Week In Review | Feb 2, 2015
Financial News

ProteoMediX financial update

ProteoMediX AG , Zurich, Switzerland   Business: Diagnostic   Date announced: 2015-01-27   Note: ProteoMediX raised CHF1 million ($1.1 million) in a second close of its series B round, bringing the total raised in the round...
BC Week In Review | Apr 14, 2014
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland   Business: Cancer, Diagnostic   Date completed: 4/9/14   Type: Venture financing   Raised: CHF3.2 million ($3.6 million)   Investors: Altos Venture; Zuercher Kantonalbank; existing investors  ...
BioCentury | Jun 4, 2012
Emerging Company Profile

ProteoMediX: Prostate's PI3K biomarkers

ProteoMedix AG is developing a multiplexed ELISA-based blood test that aims to confirm an initial PSA positive result and reduce unneeded biopsies by monitoring a quartet of biomarkers associated with alterations in PI3K signaling, a...
BC Week In Review | Jan 23, 2012
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland   Business: Cancer, Diagnostic   Date completed: 1/19/12   Type: Venture financing   Raised: CHF2.6 million ($2.7 million)   Investors: Altos Venture; private investors  ...
BC Extra | Jan 20, 2012
Financial News

ProteoMedix raises $2.7M in series A

Cancer diagnostic company ProteoMedix AG (Zurich, Switzerland) raised CHF2.6 million ($2.7 million) in a series A round led by Altos Venture with participation from private investors. ProteoMedix is developing a blood-based prostate cancer test that...
BioCentury | Oct 31, 2011
Regulation

Lessons from PSA debate

While the medical community debates a U.S. task force's recommendation against PSA screening for prostate cancer, the implications are far broader: The task force's methodology for subjectively balancing benefit and harm is being applied to...
BC Innovations | Mar 3, 2011
Cover Story

Prostate's PTEN prognosis

U.S. and European academics have separately identified new biochemical signatures that could improve prostate cancer diagnosis and monitoring. 1,2 ProteoMediX AG holds rights to the European data and plans to develop a blood-based test that...
BC Innovations | Mar 3, 2011
Distillery Techniques

Technology: Markers

This week in techniques Approach Summary Licensing status Publication and contact information Markers Serum biomarkers for prostate cancer Studies in mice and in patient samples identified serum glycoproteins that could be used for prostate cancer...
Items per page:
1 - 9 of 9